ICON Experts Outline Successful Development Strategies At Drug Information Association 50th Annual Meeting
Published: Jun 12, 2014
Dublin, Ireland, 12 June, 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its participation at the Drug Information Association (DIA) 50th Annual Meeting, taking place from June 15th in San Diego, USA.
ICON experts, including ICON’s Chief Medical Officer, Professor Brendan Buckley, will educate attendees on a range of topics, including innovative partnering models and outsourcing strategies, risk-based monitoring, functional service provision, novel adaptive design approaches and clinical outcomes assessment. Attendees will also be able to meet ICON senior executives and learn more about ICON’s range of services by visiting the ICON booth (#1305) and the Aptiv Solutions booth (#1711) in the exhibit hall.
The full programme of ICON speakers is as follows:
Tuesday, June 17th
08:00 - 09:30
Big data, big impact: new levels of strategic partnerships between sponsors and CROs
Professor Brendan Buckley, Chief Medical Officer
08:00 - 09:30
Interpreting treatment effects from Patient Reported Outcome (PRO) endpoints: patient global ratings of concept versus change.
Cicely Kerr Lead Outcomes Researcher, Commercialisation & Outcomes
View an introduction to Cicely’s presentation here.
10:30 - 12:00
Risk-based monitoring: from concept to practice.
Dr. Nick Alp, Vice President, Drug Development Services
Experience conducting studies with risk-based monitoring strategies.
Nycole Olivo, CRA, Senior Manager
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 11,100 employees operating in 38 countries.
Further information is available at www.iconplc.com
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and wellbeing worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China.